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INTRODUCTION
Recent advances in chemotherapy and radiotherapy have led to increased survival rates for patients with cancer, including hematologic malignancies. Therapy-related myeloid neoplasms (t-MNs), as defined by the World Health Organization (WHO), encompass therapy-related myelodysplastic syndrome (t-MDS) and therapyrelated acute myeloid leukemia (t-AML), and constitute the most significant complication caused by cytotoxic chemotherapy [1] . In
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DISCUSSION
Chemotherapeutic agents and ionizing radiation are wellknown carcinogens, and WHO introduced t-MNs (including t-AML and t-MDS) as a new entity of disorders related to such therapies [6] . The well-recognized leukemogenic regimens are alkylating agents and topoisomerase II inhibitors, whereas other compounds such as platinum drugs are not clearly established [7, 8] .
The latency period from the first exposure to onset of t-MNs varies. It is generally known that t-MNs secondary to alkylating agents appear 4 to 7 yr after the exposure, whereas t-MNs secondary to topoisomerase II inhibitors appear after the shorter period of 1 to 5 yr [3, 6] . The chemotherapeutic regimen of our patient included the alkylating agent cyclophosphamide, and it took 67 months from the time of exposure to chemotherapy until the development of t-MDS. Alkylating agents or radiotherapy typically cause t-MDS and induce chromosomal abnormalities involving chromosomes 5 (-5,del(5q)) and 7 (-7,del(7q)) [3, 8] . Our patient showed a complex karyotype, including monosomy 7. In contrast, t-MN secondary to topoisomerase II inhibitors is associated with 11q23 or 21q22 abnormalities [3] .
t-MDS accounts for about 20% of the MDS and is an independent adverse prognostic factor [1, 8] . Treatment options for t-MDS are limited, and allogeneic RIC-HSCT is a curative option [3] . NHL is the most common hematologic malignancy in Korea, and MZL accounts for about 17% of Korean B-cell lymphoma cases [9, 10] .
All subtypes of MZL, classified as an indolent lymphoma, are highly responsive to rituximab, but there is no cure for patients with systemic spreading [11] . There have been some reports on the coexistence of BM-involved refractory lymphoma and t-MDS [3, 12] . In a study of 17 patients with lymphoid malignancy and concurrent t-MDS, the median relapse-free survival and median overall survival was 4.3 months and 6.2 months, respectively [12] .
Considering the history of extensive cytotoxic chemotherapy, frequent poor-risk cytogenetics, and recurrent preceding malignancy, allogeneic HSCT remains the only curative treatment option for patients with refractory lymphoma and concurrent t-MDS [3, 12] . There is no established consensus on a conditioning regimen, but an RIC regimen consisting of fludarabine, melphalan, and ATG was used in the previous reports and in our patient [3] .
The simultaneous presence of refractory lymphoma and t-MN in the BM is rare. To the best of our knowledge, this is the first report in Korea. Our patient has remained free from both malignancies for 21 months after allogeneic HSCT following RIC regimen.
BM examination is necessary for restaging of the lymphoma to assess the response to therapy, or doing a workup for pancytope- 
